OBJECTIVES: To examine herpes zoster-related healthcare resource utilization in hematologic (HM) or solid tumor malignancy (STM) patients seeking care at primary-care practices in 5 European countries. METHODS: Longitudinal primary-care EMR databases (Cegedim Strategic Data) in France, Italy, Germany, Spain, and United Kingdom (UK) were analyzed retrospectively (2007-2012). Patients with HM or STM diagnoses were followed for a subsequent first herpes zoster (HZ) diagnosis (index event). HZ patients were matched with non-HZ (HM and STM) patients using propensity scores based on demographics and relevant clinical characteristics.  Patients were observed for 6 months pre-index (baseline) and 6 months post-index.  Demographics, comorbidities, pharmacotherapy, and healthcare resource utilization (office visits, specialty referrals, laboratory tests, and prescriptions) were reported with statistical significance set at p≤0.05. RESULTS: HZ patients meeting selection criteria across all 5 countries included 907 HM and 4317 STM.  Mean ages ranged 64.8±15.5 (Italy-HM) to 71.8±11.5 (France-STM); female gender varied for HM from 49% (UK) to 58% (Germany), and STM 56% (UK) to 63% (France).  Case and control populations were well balanced at baseline.  Office visits per patient were significantly higher post-index for HZ cohorts across all countries and malignancy types (except Spain HM), ranging from 0.5 more visits (Spain-STM, p=0.009,) to 2.8 more (UK-HM, p<0.001). Significantly more HZ patients had post-index specialty referrals (France-STM, 2.6% more, p=0.05; Germany-STM, 4.8% more, p=0.012), and significantly more HZ patients received prescriptions post-index in all cohorts across all countries, varying from 19.2% more patients (Spain-STM, p<0.001,) to 47.3% (UK-HM, p<0.001). Significantly more HZ patients received laboratory testing, ranging from 3.2% more patients (Italy-STM, p=0.006,) to 11.4% (UK-HM, p=0.003). CONCLUSIONS: Significantly higher healthcare resource use was incurred by HZ-afflicted HM and STM patients within 6 months of HZ diagnosis for office visits, specialty referrals, laboratory testing, and outpatient prescribing compared with matched controls across 5 European countries.